Piper Sandler lowered the firm’s price target on Cigna (CI) to $370 from $374 and keeps an Overweight rating on the shares. The company’s pioneering rebate-free PBS model will help Cigna comply with the 2026 CAA, meet the terms of its FTC settlement, and reshape public perception of PBMs, the firm says. These efforts derisk the long-term PBS growth algorithm and deserve multiple expansion, in Piper’s view.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CI:
- The Week That Was, The Week Ahead: Macro and Markets, Mar. 1
- Cigna Reaffirms 2026 Adjusted Earnings Outlook to Investors
- Brainsway says Cigna’s Evernorth to eliminate authorization requirement for TMS
- Cigna price target raised to $350 from $320 at Truist
- Cigna: Solid Execution but Uncertain PBM Economics Support Neutral Hold Rating and $300 Target